The effects of corticotropin and growth hormone releasing hormones on their respective secretory axes in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin

1994 ◽  
Vol 78 (1) ◽  
pp. 63-69 ◽  
Author(s):  
G. Ramirez
Keyword(s):  
Growth Hormone ◽  
Recombinant Human Erythropoietin ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Human Erythropoietin ◽  
Before And After

Quality of Life Improvements in Capd Patients Treated with Subcutaneously Administered Erythropoietin for Anemia

1992 ◽  
Vol 12 (1) ◽  
pp. 40-42 ◽  
Author(s):  
Juliet Auer ◽  
Gail Simon ◽  
Judith Stevens ◽  
Paul Griffiths ◽  
Deborah Howarth ◽  
...  
Keyword(s):  
Social Life ◽  
Recombinant Human Erythropoietin ◽  
Nottingham Health Profile ◽  
Hemodialysis Patients ◽  
Health Profile ◽  
Emotional Wellbeing ◽  
Household Tasks ◽  
Human Erythropoietin ◽  
Before And After

Twenty -two continuous ambulatory peritoneal dialysis (CAPD) patients, mean age 48 years, at 3 U.K. renal units were assessed with the Nottingham Health Profile (N HP) before and after treatment with recombinant human erythropoietin (r-HuEPO). Mean (SD) hemoglobin (Hb) at baseline was 7.5 (1.0) gIn/dl and 10.8 (1.5) gIn/dl at retest. There were significant improvements in energy (p<0.0001), social life (p<0.005), relationships at home (p<0.05) and leisure pursuits (p<0.05). Twelve patients, mean age 51 years, who had already completed more than 9 months on r-HuEPO treatment were reassessed to determine the changes sustained. Mean (SD) Hb at second retest was 12.8 (1.3) gm/dl. Improvement in energy continued to be significant, and emotional wellbeing showed further improvement. Problems with household tasks, which had not shown significant improvement at Test B, were now considerably reduced (p=0.016). The study showed far-reaching benefits similar to those reported in hemodialysis patients, in a population with a higher mean age and higher potential coexisting illness or disability than most reported hemodialysis studies.

Long-Term Effects of Recombinant Human Erythropoietin on Macro-and Microcirculation in Chronic Hemodialysis Patients

1993 ◽  
Vol 11 (4) ◽  
pp. 237-247 ◽  
Author(s):  
J.J.J.M. Wirtz ◽  
K.M.L. Leunissen ◽  
W. van Kuijk ◽  
E.C. Cheriex ◽  
D.W. Slaaf ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Long Term Effects ◽  
Human Erythropoietin

scholarly journals The inhibitory factors of hematopoiesis in chronic hemodialysis patients treated with recombinant human erythropoietin.

1990 ◽  
Vol 161 (3) ◽  
pp. 217-225 ◽  
Author(s):  
YUKITAKA FUKUSHIMA ◽  
YASUSHI NAKAMOTO ◽  
AKIRA B. MIURA ◽  
SHIGERU MIYAGATA ◽  
SEIGI TSUCHIDA
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Human Erythropoietin ◽  
Inhibitory Factors

Autonomic Neuropathy in Hemodialysis Patients Treated with Recombinant Human Erythropoietin

1996 ◽  
Vol 19 (10) ◽  
pp. 574-577 ◽  
Author(s):  
O.O. Stojcheva-Taneva ◽  
M.H. Polenakovic
Keyword(s):  
Blood Pressure ◽  
Autonomic Dysfunction ◽  
Recombinant Human Erythropoietin ◽  
Hemodialysis Patients ◽  
Maintenance Hemodialysis ◽  
Exercise Heart Rate ◽  
Control Group ◽  
Human Erythropoietin ◽  
Group I ◽  
Before And After

Autonomic nervous system (ANS) function was evaluated in hemodialysis patients treated with recombinant human erythropoietin (rHu-EPO) before and after therapy, in an effort to evaluate the role of anemia in the genesis of autonomic dysfunction in chronic renal failure (CRF). Studies were conducted using a battery of five cardiovascular reflex tests: Valsalva maneuver, handgrip exercise, heart rate response to standing (30:15 index), post-Valsalva rise in blood pressure and postural drop in blood pressure. The patients were divided into two groups: group I consisted of 14 patients on maintenance hemodialysis treated with rHu-EPO for one year, and group II - 13 hemodialysis patients treated with rHu-EPO for two years. The results of the tests were compared before and after the correction of anemia by rHu-EPO in each group, as well as with the control group of ten healthy subjects. Data show that renal anemia is not implicated in the genesis of ANS dysfunction in hemodialysis patients, since correction of same by rHu-EPO does not improve the autonomic dysfunction.

Sign in / Sign up

Export Citation Format

Share Document